Drs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022

By Chadi Nabhan, MD, MBA, FACP - Last Updated: August 11, 2023

In the inaugural episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Hagop Kantarjian, MD, and Elias Jabbour, MD, both of the Department of Leukemia at the University of Texas MD Anderson Cancer Center. The trio cover high-impact studies, novel treatment strategies, and controversial standard-of-care approaches for AML as well as ALL that were presented at the 2022 American Society of Hematology Annual Meeting & Exposition.

Dr. Nowakowski Gives an Inside Look at the FDA ODAC 'Yes' Vote to Polivy

Dr. Kami Maddocks: Ibrutinib Withdrawal 'Bittersweet'

Jorge Cortes, MD, on Why Balance Is Key in CML Therapy

What Are the Top Questions in ALL?

The ABCs of MM Treatment According to Rafael Fonseca, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Drs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022

Related